Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus placebo after complete surgery for high-risk localized primary gastrointestinal stromal tumor
2013-004162-34Phase 3Terminated
- Sponsor
- AB Science
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing Masitinib with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Sep 2014; status: terminated.
02
Drugs
masitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2013-004162-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004162-34.